Literature DB >> 10589891

Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors.

E J Gorak1, S M Yamada, J D Brown.   

Abstract

Community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections are not commonly recognized in healthy patients without predisposing risk. We performed a retrospective study of patients hospitalized with community-acquired MRSA infections from 1992 to 1996 in Honolulu to determine if community-acquired MRSA infections occurred in patients without known risk. Patients hospitalized within the previous 6 months or transferred from other hospitals or nursing homes were excluded. Epidemiological and clinical data were obtained from an inpatient chart review. Ten (71%) of 14 patients with community-acquired MRSA infection had no discernible characteristics of MRSA infections. Thirteen (93%) patients had skin or soft-tissue infections and one patient had MRSA pneumonia. Isolates from patients with MRSA infection were more likely to be susceptible to ciprofloxacin (P = .05), clindamycin (P = .03), and erythromycin (P = .01) than were those from MRSA-colonized patients. In our population, the majority of community-acquired MRSA infections occurred in previously healthy individuals without characteristics suggestive of MRSA transmission.

Entities:  

Mesh:

Year:  1999        PMID: 10589891     DOI: 10.1086/520437

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  65 in total

1.  40 years of methicillin resistant Staphylococcus aureus.

Authors:  A van Belkum; H Verbrugh
Journal:  BMJ       Date:  2001-09-22

2.  Recognition of two groups of methicillin-resistant Staphylococcus aureus strains based on epidemiology, antimicrobial susceptibility, hypervariable-region type, and ribotype in Finland.

Authors:  S Salmenlinna; J Vuopio-Varkila
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

3.  Immune-activating properties of Panton-Valentine leukocidin improve the outcome in a model of methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Pauline Yoong; Gerald B Pier
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

4.  Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000.

Authors:  Mark E Jones; David C Mayfield; Clyde Thornsberry; James A Karlowsky; Daniel F Sahm; Dan Peterson
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

5.  Origins of community strains of methicillin-resistant Staphylococcus aureus.

Authors:  Edwin D Charlebois; Françoise Perdreau-Remington; Barry Kreiswirth; David R Bangsberg; Daniel Ciccarone; Binh A Diep; Valerie L Ng; Kimberly Chansky; Brian R Edlin; Brian Edlin; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2004-06-01       Impact factor: 9.079

6.  Surveillance of methicillin-resistant Staphylococcus aureus in a pediatric hospital in Mexico City during a 7-year period (1997 to 2003): clonal evolution and impact of infection control.

Authors:  M E Velazquez-Meza; M Aires de Sousa; G Echaniz-Aviles; F Solórzano-Santos; G Miranda-Novales; J Silva-Sanchez; H de Lencastre
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

7.  Use of Oral Doxycycline for Community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA) Infections.

Authors:  Sanjay Bhambri; Grace Kim
Journal:  J Clin Aesthet Dermatol       Date:  2009-04

8.  High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection.

Authors:  Christina R Hermos; Pauline Yoong; Gerald B Pier
Journal:  Clin Infect Dis       Date:  2010-10-14       Impact factor: 9.079

9.  Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children.

Authors:  Kanokporn Mongkolrattanothai; Robert S Daum
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

Review 10.  Antibacterial resistance.

Authors:  Jocelyn Y Ang; Elias Ezike; Basim I Asmar
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.